Targeting Checkpoint Kinases in Pediatric Solid Tumors and Brain Tumors
As a physician-scientist, Dr. Cole is highly committed to translating scientific discoveries to the clinic. In this regard, her laboratory has performed loss of function genetic screens supporting four pediatric oncology clinical trials. She developed and leads a Children’s Oncology Group multi-institution clinical trial of the Wee1 inhibitor Adavosertib /AZD1775 and Irinotecan (ADVL1312). The Phase I dose finding portion is complete and the Phase II portion of the study is currently accruing patients to determine the clinical activity for children with relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.